Chloe Slichter
chloeslichter.bsky.social
Chloe Slichter
@chloeslichter.bsky.social
30 followers 52 following 4 posts
Immunologist / Scientific group leader @kitepharma studying CAR T cells. All views are my own.
Posts Media Videos Starter Packs
Reposted by Chloe Slichter
To be clear, these kinds of breakthroughs are going to come to a screeching halt with the current NIH funding cuts. This new treatment is only possible because of decades of basic research. What might be possible 20 years from now if we don't destroy basic research?

www.nature.com/articles/d41...
World’s first personalized CRISPR therapy given to baby with genetic disease
Treatment seems to have been effective, but it is not clear whether such bespoke therapies can be widely applied.
www.nature.com
Beautiful day for a snowshoe break in between scientific sessions at the Immune Cell Therapies: Advances in Cancer and Autoimmune Disease Keystone Symposia in Banff. Great snow & even better science! #KSCellTherapy25 @keystonesymposia.bsky.social
Reposted by Chloe Slichter
This is a list of blockbuster drugs in 2024. Guess how many can trace their origins to NIH funded research?
All of them.
Great study by the Rezvani lab exploring the relationship between the immunological synapse and NK-CAR function in response to AML. One outstanding question - with a CD38 CAR, how many cord-blood derived CAR-NK cells are undergoing fratricide? A CD38 KO could preserve NK #s and enhance NK function.
Overcoming CD226-related immune evasion in AML with CD38 CAR-engineered NK cells
www.cell.com/cell-reports...
Reposted by Chloe Slichter
Meeting report @sciimmunology.bsky.social
challenges to understanding common mechanisms in autoimmune disease
www.science.org/doi/10.1126/...
Reposted by Chloe Slichter
Science’s 2024 Breakthrough of the Year is lenacapavir, an injectable drug that demonstrated remarkable success at preventing HIV infection with one shot every 6 months.

Learn more about this year's #BOTY and other big advances in science: scim.ag/3BrCtUn
Reposted by Chloe Slichter
Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy
www.cell.com/cell-stem-ce...
Reposted by Chloe Slichter
"If talent and opportunity were equally distributed, the average winner would come from a middle income background.

The reality?

The average laureate grew up in a household just below the top 10%. More than 50% come from the top 5%"

By Torsten Bell

www.theguardian.com/commentisfre...
The science behind winning a Nobel Prize? Being a man from a wealthy family | Torsten Bell
A lot of talent is wasted in a world where more than half of laureates come from households in the richest 5%
www.theguardian.com
Reposted by Chloe Slichter
Fascinating study where they label CAR T cells and follow their trafficking in patients! Immediate biodistribution is to the liver and spleen, and they can see whether the Car goes into extramedullary masses. What explains differences between patients?
Up next, the #ASH24 #MyelomaSky **Clinical Abstracts - RRMM @ash-hematology.bsky.social
1029 CAR-T Cell Therapy in Advanced Myeloma with EMD In Vivo Imaging and Molecular Monitoring Study (CARAMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-CT and PET-MRI
ash.confex.com/ash/2024/web...
Paper: CAR-T Cell Therapy in Advanced Myeloma with Extramedullary Disease – an <em>In Vivo</Em> Imaging and Molecular Monitoring Study (CARAMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-...
ash.confex.com
Good morning from Philadelphia ☀️ Here for the Cell Therapy for Autoimmune Disease Summit. Looking forward to learning more about the application of synthetic biology in autoimmunity #celltherapy